T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Meta Platforms (Facebook)
META
|
+$2.16B |
| 2 |
GE Aerospace
GE
|
+$1.93B |
| 3 |
Alphabet (Google) Class C
GOOG
|
+$1.62B |
| 4 |
Eli Lilly
LLY
|
+$1.59B |
| 5 |
SPLK
Splunk Inc
SPLK
|
+$1.38B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Tesla
TSLA
|
+$2.72B |
| 2 |
Booking.com
BKNG
|
+$2.61B |
| 3 |
RHT
Red Hat Inc
RHT
|
+$1.62B |
| 4 |
JPMorgan Chase
JPM
|
+$1.43B |
| 5 |
State Street
STT
|
+$1.29B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 18.46% |
| 2 | Technology | 17.53% |
| 3 | Financials | 14.18% |
| 4 | Consumer Discretionary | 14.02% |
| 5 | Communication Services | 9.56% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
326
Canadian Natural Resources
CNQ
$98.1B
| $299M | 0.05% |
25,291,469
-2,477,236
| -9% | -$33.3M |
|
|
ACC
327
DELISTED
American Campus Communities, Inc.
ACC
| $299M | 0.05% |
7,216,769
-243,492
| -3% | -$10.1M |
|
328
Aramark
ARMK
$16.1B
| $298M | 0.05% |
14,229,617
-28,479,127
| -67% | -$739M |
|
|
LOXO
329
DELISTED
Loxo Oncology, Inc
LOXO
| $296M | 0.05% |
2,116,328
-106,509
| -5% | -$16.2M |
|
330
Descartes Systems
DSGX
$6.62B
| $296M | 0.05% |
11,201,204
-276,521
| -2% | -$8.09M |
|
|
PSB
331
DELISTED
PS Business Parks, Inc.
PSB
| $296M | 0.05% |
2,261,313
-159,839
| -7% | -$21.2M |
|
332
Martin Marietta Materials
MLM
$32.7B
| $296M | 0.05% |
1,721,334
-19,084
| -1% | -$3.39M |
|
|
B
333
Barrick Mining
B
$67.3B
| $294M | 0.05% |
21,745,009
+2,551,104
| +13% | +$33M |
|
334
Automatic Data Processing
ADP
$110B
| $293M | 0.05% |
2,237,923
+617,283
| +38% | +$87.1M |
|
335
EastGroup Properties
EGP
$11B
| $293M | 0.05% |
3,192,225
-112,816
| -3% | -$10.9M |
|
336
Enovis
ENOV
$1.48B
| $292M | 0.05% |
8,127,456
+1,180,248
| +17% | +$55.1M |
|
|
LLL
337
DELISTED
L3 Technologies, Inc.
LLL
| $292M | 0.05% |
1,681,439
-7,188
| -0.4% | -$1.38M |
|
338
Pediatrix Medical
MD
$2.14B
| $290M | 0.05% |
8,800,851
+377,903
| +4% | +$15.2M |
|
339
CME Group
CME
$96.1B
| $290M | 0.05% |
1,540,361
-575,357
| -27% | -$106M |
|
340
Neurocrine Biosciences
NBIX
$15.3B
| $286M | 0.05% |
4,009,363
-1,878,121
| -32% | -$180M |
|
341
Synchrony
SYF
$26.1B
| $283M | 0.05% |
12,071,700
-6,431,991
| -35% | -$174M |
|
342
Linde
LIN
$220B
| $283M | 0.05% |
+1,812,220
| New | +$286M |
|
343
RTX Corp
RTX
$297B
| $282M | 0.05% |
4,211,818
-536,808
| -11% | -$42.1M |
|
344
Fortune Brands Innovations
FBIN
$5.78B
| $281M | 0.05% |
8,643,622
+3,722,293
| +76% | +$141M |
|
|
JBTM
345
JBT Marel
JBTM
$6.1B
| $281M | 0.05% |
3,906,790
-95,420
| -2% | -$8.46M |
|
346
AXIS Capital
AXS
$7.3B
| $280M | 0.05% |
5,427,973
+572,177
| +12% | +$31.3M |
|
347
Douglas Emmett
DEI
$1.99B
| $280M | 0.05% |
8,191,992
-952,786
| -10% | -$34.2M |
|
348
Western Alliance Bancorporation
WAL
$8.92B
| $278M | 0.05% |
7,029,149
+119,421
| +2% | +$5.65M |
|
|
COHR
349
DELISTED
Coherent Inc
COHR
| $277M | 0.05% |
2,620,233
-183,016
| -7% | -$23.5M |
|
350
Flowers Foods
FLO
$1.6B
| $277M | 0.05% |
14,987,472
-292,795
| -2% | -$5.61M |
|
Similar funds
T. Rowe Price Associates's Q4 2018 Portfolio in Review
As of Q4 2018, T. Rowe Price Associates held 2,656 positions worth $591B, down 14% from $685B the previous quarter. Its ten largest holdings account for 20% of the portfolio.
T. Rowe Price Associates's Q4 2018 filing shows 75 new, 1,551 increased, 819 reduced and 97 closed positions. Its largest new stake was StoneCo: 28,883,228 shares worth $519M. The largest sale was Tesla, an estimated $2.72B.
By sector, the portfolio is most concentrated in Healthcare at 18% of assets, up from 18% a quarter earlier, followed by Technology and Financials.
- T. Rowe Price Associates's largest Q4 2018 buy was StoneCo: 28,883,228 shares worth $519M.
- T. Rowe Price Associates added most to Meta Platforms (Facebook) in Q4 2018, an estimated $2.16B increase.
- T. Rowe Price Associates's biggest Q4 2018 reduction was Tesla, cutting an estimated $2.72B.
- T. Rowe Price Associates fully exited Aetna Inc in Q4 2018, selling an estimated $600M.
- T. Rowe Price Associates's ten largest holdings make up 20% of its $591B portfolio in Q4 2018.
- T. Rowe Price Associates opened 75 new positions and closed 97 in Q4 2018.
- T. Rowe Price Associates's portfolio value fell 14% quarter-over-quarter to $591B.
Based on T. Rowe Price Associates's 13F filing for Q4 2018, filed 14 Feb 2019.